Navigation Links
MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
Date:2/1/2011

MARIETTA, Ga., Feb. 1, 2011 /PRNewswire/ -- MiMedx Group, Inc.  (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that they will be attending the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, February 15 – 19, 2011.  The meeting will be held at the San Diego Convention Center in San Diego, California.  

MiMedx reported that it will have a sizable presence at AAOS this year to present the potential  numerous trauma, sports medicine, spine and wound care applications that are being developed with the Company's three technologies, CollaFix™, HydroFix™ and its newest technology, AmnioFix™.   During the week of the conference, MiMedx plans to hold various meetings with physicians and scientists to demonstrate the benefits of its current and potential products and implants and share the progress being made in its CollaFix™ technology.

MiMedx recently acquired its AmnioFix™ technology through the acquisition of Surgical Biologics, the leading processor of amniotic tissue and the developer of the patent-pending Purion® process.

MiMedx Group will be located in Booth 5915 at the San Diego Conference Center.  

About MiMedx

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform processing technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures. MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. Stunning Attendance for ChemOutsourcing Show on September 8-9 in Long Branch, NJ
6. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
7. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
8. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
9. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
10. Early-Bird Pricing Ends Soon for MichBio Expo Attendees and Exhibitors; Award Nominations Due Nov. 1
11. National Ergonomics Expo Sees 86% On-Site Exhibitor Renewal Rate for 2009; New Products from Contour Design, Equipois, Goldtouch and Herman Miller Win 2008 NECE Attendees Choice New Product Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 2017 , ... During HIMSS 2017, CloudMine, a secure, cloud-based ... partnership with Redox, a leader in cloud-based healthcare integration and API services. The ... data secure in the cloud. , The digital health developers, and various healthcare ...
(Date:2/21/2017)... , ... February 21, 2017 , ... The medical potential ... their use, in multiple areas of medicine, due to their differentiating characteristics. Stem cells ... they have the ability to be induced to become tissue or organic-specific cells with ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 /PRNewswire/ ... that apatorsen results from two randomized Phase 2 clinical trials ... 2017 Genitourinary Cancers Symposium, held February 16 th - 18 ... from trials in bladder and prostate cancers demonstrated apatorsen was ... standard-of-care treatments. ...
(Date:2/21/2017)... , Feb. 21, 2017   Invitae Corporation ... information companies, today announced that members of the company,s ... 37th Annual Health Care Conference on Monday, March 6, ... Pacific in Boston, Massachusetts . ... may be accessed by visiting the investors section of ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
Breaking Biology News(10 mins):